Eosinophilic fasciitis: a case series with an emphasis on therapy and induction of remission

• Main Authors: Rechelle Tull, William D Hoover III, Jacqueline F De Luca, William W Huang, Joseph L Jorizzo
• Format: Article
• Language: English
• Published: BioExcel Publishing Ltd 2018-10-01
• Series: Drugs in Context
• Subjects: connective tissue diseases; corticosteroids; dermatology; drug therapy; eosinophilic fasciitis; immunosuppressive agents; methotrexate; prednisone
• Online Access: https://www.drugsincontext.com/eosinophilic-fasciitis-a-case-series-with-an-emphasis-on-therapy-and-induction-of-remission
• ISSN: 1740-4398; 1740-4398

Eosinophilic fasciitis is an uncommon connective tissue disorder that affects patients of all ages, resulting in significant morbidity. Systemic corticosteroids can induce remission of disease. However, there is no universally accepted treatment ladder for eosinophilic fasciitis. This case series evaluates treatment efficacy in patients with eosinophilic fasciitis seen at Wake Forest University Department of Dermatology outpatient clinics. Patient charts were screened using ICD-9 diagnosis code 710.9 (unspecified diffuse connective tissue disease) to identify patients with eosinophilic fasciitis (n=10) seen at our institution. Patients were treated for an average 24 months with a combination of methotrexate and prednisone therapy, unless one or both were contraindicated, with each medication tapered conservatively to prevent disease flares. Alternate treatments included mycophenolate mofetil with prednisone, azathioprine with prednisone, prednisone monotherapy, and methotrexate monotherapy. Disease remission off therapy and on low-dose therapy was 66 and 70%, respectively. Our first-line therapy of concomitant methotrexate and prednisone is well-tolerated and effective for managing patients with eosinophilic fasciitis. Our study was limited to cases seen at a single academic institution.